Cardiovascular safety and GLP-1 receptor agonists

Practical Diabetes

Volumn 30, Issue 6, 2013, Pages 242-245

  Carty, David M ^a,b   Drummond, Russell ^a   Fisher, Miles ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular outcomes; Cardiovascular safety; GLP 1 receptor agonists

Indexed keywords

DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 84881325320     PISSN: None     EISSN: 20472900     Source Type: Journal    
DOI: 10.1002/pdi.1785     Document Type: Review

References (13)

1. Carty DM, et al. Cardiovascular safety and DPP-IV inhibitors. Pract Diabetes 2013;30(2):78-81.
2. Ratner R, et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011;10:22.
3. Best JH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011;34(1):90-5.
4. Marso SP, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011;8(3):237-40.
5. Monami M, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011; 2011:215764.
6. Sun F, et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Res Clin Pract 2012; 98(3):386-95.
7. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus. http://clinicaltrials.gov/show/ NCT01144338.
8. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation (LEADER®). http://clinicaltrials. gov/ show/NCT01179048.
9. Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA). http://clinicaltrials.gov/ show/NCT01147250.
10. Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND). http://clinicaltrials. gov/show/NCT01394952.
11. Sivertsen J, et al. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012; 9(4):209-22.
12. Lonborg J, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33(12): 1491-9.
13. Nathanson D, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 2012; 55(4):926-35.